When the Quality of Evidence Just Doesn't Make the Grade in Cancer Care

Maurie Markman, MD
Published: Friday, May 10, 2019
Maurie Markman, MD
Maurie Markman, MD
Some subjects in clinical medicine appear to be out-of bounds for open discussion. Consider the recent story in an otherwise prudent newspaper (The Jerusalem Post) that a pharmaceutical company that had only tested a novel drug in mice would have “a cure for cancer within a year.”1 Of course, once it was printed in this newspaper, other media outlets reported the same nonsense. So, the question to be asked is: To what degree should reputable journalists and mainstream news organizations ensure at least a modest degree of authenticity in their reporting?
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication